{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:07:57Z","timestamp":1791068877645,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018088","name":"University of Virginia School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clinbiochem.2024.110747","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T16:11:30Z","timestamp":1710259890000},"page":"110747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Spironolactone metabolite causes falsely increased progesterone in the Abbott Architect immunoassay"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-5756","authenticated-orcid":false,"given":"Kwabena A.N.","family":"Sarpong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Hee Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"McCartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joesph R.","family":"Wiencek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A.L.","family":"Bazydlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2024.110747_b0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ogc.2014.10.003","article-title":"Progesterone and the luteal phase: a requisite to reproduction","volume":"42","author":"Mesen","year":"2015","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00198","article-title":"Progesterone-related immune modulation of pregnancy and labor","author":"Shah","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.clinbiochem.2024.110747_b0015","series-title":"Physiology","author":"Rosner","year":"2022"},{"key":"10.1016\/j.clinbiochem.2024.110747_b0020","unstructured":"Spironolactone (Oral Route) Proper Use - Mayo Clinic. https:\/\/www.mayoclinic.org\/drugs-supplements\/spironolactone-oral-route\/proper-use\/drg-2007153Accessed 28 Nov 2023."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0025","unstructured":"Immunosuppression by Progesterone in Pregnancy - Julia Szekeres-Bartho - Google Books. https:\/\/books.google.com.gh\/books?hl=en&lr=&id=U8DTv_R5lMkC&oi=fnd&pg=PA1&ots=tG_Cw7Z4Z5&sig=uGpRuzP6pPN26qGwd-AJYp2zsrk&redir_esc=y#v=onepage&q&f=false. Accessed 29 Nov 2023."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011039","article-title":"Key to life: physiological role and clinical implications of progesterone","author":"Nagy","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0035","doi-asserted-by":"crossref","unstructured":"U. Andreasson, A. Perret-Liaudet, L. van Waalwijk, J.C. van Doorn, et al (2015) A Practical Guide to Immunoassay Method Validation. Front. Neurol. 6.","DOI":"10.3389\/fneur.2015.00179"},{"key":"10.1016\/j.clinbiochem.2024.110747_b0040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1373\/clinchem.2013.220012","article-title":"Tacrolimus measurement: building a better immunoassay","volume":"60","author":"Gounden","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0045","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1210\/en.2014-7534","article-title":"Steroid assays and endocrinology: best practices for basic scientists","volume":"155","author":"Auchus","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinbiochem.2024.110747_b0050","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1515\/cclm-2020-1786","article-title":"A case of interference in testosterone, DHEA-S and progesterone measurements by second generation immunoassays","volume":"59","author":"Cresta","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1373\/jalm.2016.020123","article-title":"Accuracy of a direct progesterone immunoassay","volume":"1","author":"Shankara-Narayana","year":"2016","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0060","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jalm\/jfz010","article-title":"AACC guidance document on biotin interference in laboratory tests","volume":"5","author":"Li","year":"2020","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0065","first-page":"S43","article-title":"Interference testing","volume":"29","author":"Dimeski","year":"2008","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.clinbiochem.2024.110747_b0075","series-title":"Spironolactone","author":"Patibandla","year":"2022"},{"key":"10.1016\/j.clinbiochem.2024.110747_b0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","article-title":"Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability","volume":"8","author":"Karim","year":"1978","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0085","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/ejhf.1802","article-title":"Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial","volume":"22","author":"de Denus","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0028-1095668","article-title":"Interference by spironolactone of radioassays for progesterone and estrogen","volume":"7","author":"YoungLai","year":"1975","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0095","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/jcem-41-4-777","article-title":"Effect of spironolactone on sex hormones in man","volume":"41","author":"Stripp","year":"1975","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0100","doi-asserted-by":"crossref","unstructured":"I. Terai, K. Yamano, N. Ichihara, J. Arai, K. Kobayashi. (1999) Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia. Arch. Dis. Child Fetal. Neonatal. Ed. 81:F179 LP-F183.","DOI":"10.1136\/fn.81.3.F179"},{"key":"10.1016\/j.clinbiochem.2024.110747_b0105","unstructured":"CLSI. Interference Testing in Clinical Chemistry. 3rd ed. CLSI guideline EP07. Wayne, PA:Clinical and Laboratory Standards Institute; 2018."},{"key":"10.1016\/j.clinbiochem.2024.110747_b0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt1976192177","article-title":"Spironolactone. III. canrenone-maximum and minimum steady-state plasma levels","volume":"19","author":"Karim","year":"1976","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912024000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912024000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T11:59:13Z","timestamp":1712145553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912024000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":22,"alternative-id":["S0009912024000419"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2024.110747","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone metabolite causes falsely increased progesterone in the Abbott Architect immunoassay","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2024.110747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110747"}}